~ Buy the JESDUVROQ (daprodustat) Drug Profile, 2024 PDF Report in the Report Store ~

JESDUVROQ Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Jesduvroq, and when can generic versions of Jesduvroq launch?

Jesduvroq is a drug marketed by Glaxosmithkline and is included in one NDA. There are six patents protecting this drug.

This drug has forty-two patent family members in thirty-one countries.

The generic ingredient in JESDUVROQ is daprodustat. One supplier is listed for this compound. Additional details are available on the daprodustat profile page.

DrugPatentWatch^® Generic Entry Outlook for Jesduvroq

Jesduvroq will be eligible for patent challenges on February 1, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 1, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for JESDUVROQ?
What are the global sales for JESDUVROQ?
What is Average Wholesale Price for JESDUVROQ?

Summary for JESDUVROQ

International Patents:	42
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	46
Clinical Trials:	1
Patent Applications:	19
Drug Prices:	Drug price information for JESDUVROQ
What excipients (inactive ingredients) are in JESDUVROQ?	JESDUVROQ excipients list
DailyMed Link:	JESDUVROQ at DailyMed

Drug patent expirations by year for JESDUVROQ

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for JESDUVROQ

Generic Entry Date for JESDUVROQ^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: NEW CHEMICAL ENTITY NDA: 216951 Dosage: TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for JESDUVROQ

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
GlaxoSmithKline	Phase 4
USRC Kidney Research	Phase 4

See all JESDUVROQ clinical trials

US Patents and Regulatory Information for JESDUVROQ

JESDUVROQ is protected by six US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of JESDUVROQ is ⤷ Sign Up.

This potential generic entry date is based on NEW CHEMICAL ENTITY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting JESDUVROQ

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF TREATING ANEMIA

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Prolyl hydroxylase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE

FDA Regulatory Exclusivity protecting JESDUVROQ

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-005	Feb 1, 2023		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-004	Feb 1, 2023		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-005	Feb 1, 2023		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up		Y		⤷ Sign Up
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-005	Feb 1, 2023		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-001	Feb 1, 2023		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-003	Feb 1, 2023		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for JESDUVROQ

See the table below for patents covering JESDUVROQ around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Japan	2020533396	ＧＳＫ１２７８８６３の結晶形及びその製造方法並びに医薬用途	⤷ Sign Up
Canada	3112277	FORME CRISTALLINE DE GSK1278863 ET SON PROCEDE DE PREPARATION ET SON UTILISATION PHARMACEUTIQUE (CRYSTAL FORM OF GSK1278863 AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF)	⤷ Sign Up
China	101505752	Prolyl hydroxylase inhibitors	⤷ Sign Up
China	111093668	GSK1278863 的晶型及其制备方法和制药用途 (CRYSTAL FORM OF GSK1278863 AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF)	⤷ Sign Up
Eurasian Patent Organization	018220	ИНГИБИТОРЫ ПРОЛИЛГИДРОКСИЛАЗ (PROLYL HYDROXYLASE INHIBITORS)	⤷ Sign Up
South Korea	101411816		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration